DiaMedica Therapeutics' (DMAC) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• DiaMedica Therapeutics (DMAC) has had its "sell (D-)" rating reiterated by Weiss Ratings, while some analysts maintain a "buy" rating with varying price targets.
• Notable insider activity includes Jan Stahlberg acquiring over 1.5 million shares at $3.50 each, increasing his stake by nearly 30%.
• The stock has recently traded around $6.96 with a consensus rating of "Moderate Buy" and a median price target of $12.33.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report)'s stock had its "sell (d-)" rating reiterated by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

DMAC has been the subject of several other research reports. HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a research note on Friday, August 15th. Lake Street Capital increased their price target on DiaMedica Therapeutics from $11.00 to $14.00 and gave the stock a "buy" rating in a research note on Friday, July 18th. Craig Hallum increased their price target on DiaMedica Therapeutics from $8.00 to $11.00 and gave the stock a "buy" rating in a research note on Friday, July 18th. Finally, Wall Street Zen raised DiaMedica Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

DiaMedica Therapeutics Price Performance

DMAC traded up $0.10 during trading hours on Wednesday, hitting $6.96. 142,004 shares of the stock were exchanged, compared to its average volume of 357,186. The stock has a 50-day simple moving average of $6.13 and a 200-day simple moving average of $4.72. DiaMedica Therapeutics has a 12 month low of $3.19 and a 12 month high of $7.49. The stock has a market cap of $359.76 million, a price-to-earnings ratio of -10.09 and a beta of 1.40.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, hitting the consensus estimate of ($0.18). Sell-side analysts expect that DiaMedica Therapeutics will post -0.59 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Jan Stahlberg bought 1,542,857 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was acquired at an average price of $3.50 per share, with a total value of $5,399,999.50. Following the completion of the purchase, the insider directly owned 6,764,465 shares of the company's stock, valued at $23,675,627.50. This represents a 29.55% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders bought a total of 2,542,857 shares of company stock worth $11,358,598 over the last ninety days. Company insiders own 7.30% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its holdings in shares of DiaMedica Therapeutics by 24.4% during the second quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company's stock valued at $74,000 after purchasing an additional 3,709 shares during the last quarter. World Investment Advisors lifted its holdings in shares of DiaMedica Therapeutics by 17.0% during the first quarter. World Investment Advisors now owns 25,650 shares of the company's stock valued at $97,000 after purchasing an additional 3,735 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of DiaMedica Therapeutics during the second quarter valued at $29,000. Bank of America Corp DE lifted its holdings in shares of DiaMedica Therapeutics by 3,710.3% during the second quarter. Bank of America Corp DE now owns 8,497 shares of the company's stock valued at $33,000 after purchasing an additional 8,274 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in shares of DiaMedica Therapeutics during the second quarter valued at $49,000. Institutional investors own 10.12% of the company's stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.